Immupharma Share Discussion Threads

[abbynat] 07/9/2020 16:33

well. i make that 2 more days or 3.And then what? poss good news? Because it needs it!

[abbynat] 07/9/2020 10:54

i think i'll have to consult my lawyer, phsychiatrist and psychologist my gp and the fireman who lives next door to make any sense of this rns!

[wigwammer] 06/9/2020 09:23

Proving lupuzor works is one thing. Getting it to a phase 3 result and benefiting from the multiple rerating on the approach is quite another. Worth remembering that many made fantastic returns here last time (and others bought near the top).

[njb67] 04/9/2020 18:08

Getting FDA to to approve the clinical trial study design (SPA) is one thing.
Proving Lupuzor works in that clinical trial is totally different.

Worth remembering that the FDA previously granted Lupuzor the approval to start Phase III with a Special Protocol Assessment (SPA). This was the phase 3 trial that failed in 2018.

[nico115] 04/9/2020 10:56

If SPA is successful what price will we be ? 20p?And if not 8p and then rally back up to 12p ready for the next SPA?

[halfbutt] 03/9/2020 09:25

All those sells but still at 13p ????

[cap160] 02/9/2020 21:44

https://www.proactiveinvestors.co.uk/companies/news/928063/immupharma-raises-65mln-to-invest-in-pipeline-of-up-and-coming-drugs-928063.html

[bbluesky] 02/9/2020 20:51

Belief. They sure have belief and increasingly institutions do. If you can stand being kicked in the teeth on a regular basis, you may come out smiling: this is one aggressive company.

[for fx sake] 02/9/2020 19:03

Well, if you're right then it looks like a minimal risk punt for those 'benevolent' new investors.

[nobbygnome] 02/9/2020 18:58

It won't be rejected outright. They may be asked to make a few amendments but in an indication like lupus with such a high unmet need it won't be rejected.

[for fx sake] 02/9/2020 18:49

Rossannan,Hopefully that will be the case here too. I suppose it all depends on the SPA outcome really.The use of the phrase "In response to investor demand" to justify the dilution implies that it was pushed for by external influences rather than carefully planned by the BoD as a strategic move.The investors must be expecting good news though. I can't imagine that, even with the hefty discount they got, they will get much protection from the downside if rejection occurs.

[colsmith] 02/9/2020 16:57

But SK - the RNS stated oversubscribed - just what are these guys so keen for then?

[nobbygnome] 02/9/2020 15:45

>> s_k

I have great respect for you and your opinions but on this occasion we are going to have to agree to disagree. Shareholder value and IMM management are two phrases which should never be in the same sentence.

[loafofbread] 02/9/2020 13:59

How Tim was ever allowed to be in involved in another pharma company after Alizyme is beyond me.

That turned out to be one big con and I suspect the same here.

[sicilian_kan] 02/9/2020 13:56

No they don't and they didn't then either. It is just sensible to fund a company for all outcomes not the most favourable outcome. As it transpired, the 144p placing was the best thing management have ever done.

[halfbutt] 02/9/2020 13:54

Drawing comparisons to the 144p era is a worry...does that mean they already know the outcome of the spa and are raising funds like they did before the phase 111 failure

[sicilian_kan] 02/9/2020 13:30

Hi nobby, I disagree on this one. The SPA application may or may not be successful. I hope so, but we will have to see. What they have done is to fund the company should it not be successful (as the share price would then be significantly damaged) and so it is better to do that now rather than after the event. This is no different to the 144p fundraising before the P3 results. Nothing at all to do with lining pockets, just sensible management.

[nobbygnome] 02/9/2020 13:07

>> llol

Yes I should learn that IMM is a shocker of a company. Why on earth didn't they wait until after the announcement of the success of the SPA. The answer is obvious, they are not interested in the current shareholders and just want to line the pockets of some of their mates in the City. Absolutely dreadful.....

[zb27] 02/9/2020 12:22

Without a doubt, a very disappointing RNS, did not expect that at all.

However there are some real positives.The positives are that they are now fully funded to 2023, so hopefully no more dilution, hugely derisked for any new investors! There are major institutions who are now on board, and they were desperate to invest. And this should light the fire for other institutions to also invest.

A number of TR1's should be released next week once the shares are placed, which will reveal who they are, as these institutions will undoubtedly surpass the 3% notification limit.

Why such a big discount to yesterdays share price? Well they have probably been negotiating this deal for a few months, when the share price has been bouncing around 13-14p. Only in the last week it has motored towards 17p, difficult to go back and renegotiate, you lose all credibility.

Why not raise funds after some major news? Well clearly they want to benefit from the news (wouldn't we all), and want to be in BEFORE any such news is released, and before the P3 trial for Lupuzor starts in the next few months.

For long term investors, i guess its patience patience patience.

[lord loads of lolly] 02/9/2020 11:49

nobbygnome - quick reminder on your words of wisdom from 26/8/2020 "I reckon they have to get the SPA answer by Sept 7th so not long to wait. Surely it has to go up ahead of that answer from the FDA because it would be very surprising if the SPA was rejected."
IMM's closing share price on 26/8/2020: 14p. IMM's current SP: 12.9p. So far so bad, nob. And only 5 days to go for your prediction to redeem itself,